Oscar Health, Inc. (OSCR) Company Overview

What does Oscar Health do?

Oscar Health, Inc. is a New York Stock Exchange-listed health insurer and healthcare technology company trading under OSCR. It was founded in 2012 to redesign individual health insurance around a consumer-facing digital experience. The company’s stated mission is to make a healthier life accessible and affordable for all, but its economic core is more specific: Oscar prices and underwrites Affordable Care Act-compliant health plans, builds provider networks, collects premiums, pays medical claims, and uses its technology stack to steer members toward appropriate care.

Which offerings define the business?

Oscar’s insurance business serves individuals and families buying coverage through federal or state marketplaces, off-exchange channels, and employer-funded Individual Coverage Health Reimbursement Arrangements, or ICHRAs. Plans span the ACA metal tiers from Catastrophic through Platinum. Oscar also operates +Oscar, which offers technology capabilities to providers and payors, and it expanded into brokerage and enrollment infrastructure through the 2025 acquisitions of Lucie, IHC Specialty Benefits, and Healthinsurance.org. The 2025 Form 10-K describes the resulting model as insurance, technology services, brokerage, and enrollment tools built on one full-stack platform.

How does Oscar Health make money?

Oscar makes substantially all of its revenue from direct policy premiums. Members and the federal government, through premium tax credits, fund premiums. Oscar then pays medical and pharmacy claims, broker commissions, exchange fees, operating costs, and reinsurance costs. Investment income on the insurer’s cash and securities portfolio adds a smaller but useful revenue stream. In Q1 2026, premium revenue was $4.581 billion, investment income was $60.6 million, and other revenue was $5.7 million, showing that the business remains overwhelmingly insurance-led.

What converts premium revenue into profit?

The most important formula is medical loss ratio, or medical expense divided by premium before ceded quota-share reinsurance. A lower MLR generally leaves more premium available for administration and profit, but a very low first-quarter ratio should not be annualized blindly because deductibles, new-member behavior, reserve development, and risk adjustment create seasonality. Oscar also uses quota-share and excess-of-loss reinsurance to reduce capital requirements and protect against high-cost claims.

Why is risk adjustment central to Oscar’s model?

ACA risk adjustment transfers money from plans with lower-than-average risk scores to plans with higher-risk populations. Oscar must estimate its relative position before complete market data arrives, sometimes up to twelve months later. At March 31, 2026, Oscar reported a net risk adjustment payable of $3.974 billion. For Q1 2026, estimated risk adjustment payables equaled about 24% of direct policy premium revenue. That makes coding quality, member morbidity estimates, competitor behavior, and market growth central to reported revenue—not merely accounting details.

What did Oscar Health’s latest quarter show?

Oscar’s first-quarter 2026 results were unusually strong. Revenue increased 52.6% year over year to $4.647 billion as membership and rate increases more than offset a larger risk adjustment accrual. Operating income more than doubled to $704.1 million, while net income attributable to Oscar reached $679.0 million, or $2.07 per diluted share.

How fast did membership grow?

The quarter also generated $2.619 billion of operating cash flow versus $878.5 million a year earlier, although timing of premiums, claims, risk adjustment, and CMS balances makes quarterly insurer cash flow volatile. Purchases of property, equipment, and capitalized software were only $8.8 million, so the business is not physically capital-intensive in the way a hospital system or manufacturer is.

Why did 2025 expose Oscar’s underwriting sensitivity?

The latest quarter looks strong, but the full-year baseline shows why Oscar must be analyzed through an insurance cycle rather than a single quarter. In 2025, revenue rose to approximately $11.7 billion from $9.2 billion in 2024, yet the company swung from operating income of $57.3 million to an operating loss of $396.4 million. The medical loss ratio rose from 81.7% to 87.4%, driven by higher average market morbidity, a larger net risk adjustment transfer accrual, and higher utilization that was not fully offset by risk adjustment.

What changed between annual loss and quarterly profit?

This contrast is the central analytical tension. Oscar’s technology may lower administrative friction, but insurance profitability still depends on pricing medical risk accurately. First-quarter claims are also seasonally favorable because members have not fully met deductibles and newer members may take time to use care. Researchers should therefore compare full-year MLR and operating margin with each quarterly update rather than treating Q1 as a steady-state run rate.

Which turning points shaped Oscar Health today?

Oscar’s history is best understood as a sequence of strategic shifts from digital insurance startup to scaled ACA carrier and broader consumer-health platform.

1. 2012
   Oscar was founded with a consumer-first, technology-led insurance proposition. That origin still defines its brand and software investment.
2. 2014
   The company began selling ACA individual-market coverage, tying its economics to marketplace regulation, premium subsidies, and risk adjustment.
3. 2021
   Oscar completed its initial public offering and adopted a dual-class structure, preserving founder-linked voting control after listing.
4. 2023
   Mark Bertolini became CEO while co-founder Mario Schlosser shifted toward technology leadership, separating insurance operating leadership from platform development.
5. 2024
   Oscar achieved full-year operating income and positive adjusted EBITDA, demonstrating that scale and cost discipline could produce profitability.
6. 2025
   The company acquired Lucie, IHC Specialty Benefits, and Healthinsurance.org to build ICHRA shopping, brokerage, and enrollment capabilities, while underwriting pressure produced a full-year loss.
7. 2026
   Oscar entered the year with roughly 3.4 million members selected during open enrollment, a new $475 million revolver, and a strategy centered on consumer-driven healthcare shopping.

What did the leadership transition change?

Bertolini brought decades of managed-care operating experience, while Schlosser remained focused on technology and co-founder Joshua Kushner retained board influence. In April 2026, Oscar appointed Siddhartha Sankaran as independent chair, adding separation between board leadership and the founder group. The combination suggests a governance model that seeks professional insurance discipline without abandoning the technology-led thesis.

What gives Oscar Health a competitive advantage?

Oscar competes with national insurers, regional carriers, Medicaid-focused plans entering ACA exchanges, and local Blue Cross organizations. It does not possess the hospital ownership, Medicare scale, or employer-account breadth of the largest diversified insurers. Its argument instead rests on a narrower set of resources: a cloud-native platform, a consumer-facing brand, personalized engagement, broker distribution, selected provider networks, and years of individual-market data.

Where is the moat strongest—and weakest?

The advantage is most credible when technology improves measurable insurance outcomes: lower service cost, stronger retention, better coding, more effective care navigation, or broker productivity. The 2025 Form 10-K notes that the vast majority of membership is acquired through brokers, which limits pure direct-to-consumer economics and creates commission competition. Oscar also intentionally contracts with selected provider systems rather than every system in a market, helping reimbursement negotiations but potentially narrowing choice.

How financially strong is Oscar Health?

Oscar’s first-quarter 2026 Form 10-Q reported $4.805 billion of cash and cash equivalents, $1.995 billion of short-term investments, $9.290 billion of total assets, and $1.667 billion of total stockholders’ equity. Long-term debt was $430.9 million, consisting primarily of $410 million principal of 2.25% convertible notes due 2030 and $35 million principal of 7.25% convertible notes due 2031. A $475 million secured revolving facility was undrawn at quarter-end and can potentially expand by another $100 million.

How should cash flow be interpreted?

Oscar’s free-cash-flow conversion appears high if one simply subtracts $8.8 million of capitalized software and equipment purchases from operating cash flow. That calculation is mechanically correct but economically incomplete. Insurer cash flow can swing with premium collections, claims settlement, reinsurance receipts, and risk adjustment payments. The better financial-strength test combines liquidity, statutory capital at insurance subsidiaries, annual underwriting profitability, and the ability to fund growth without repeated equity issuance.

Who owns Oscar Health stock, and why does control matter?

Oscar has Class A shares with one vote each and Class B shares with twenty votes each. The dual-class structure makes voting power far more concentrated than economic ownership. According to the 2026 proxy statement, 265.5 million Class A shares and 35.6 million Class B shares were outstanding on April 10, 2026.

How should investors interpret the governance model?

Concentrated control can support long-horizon investment and protect strategy from short-term market pressure. It can also reduce accountability to Class A holders and make a change of control difficult without founder-linked approval. Oscar’s board has added independent leadership and maintains independent audit, compensation, and governance committees, but the voting structure remains the decisive governance fact.

Which KPIs best explain Oscar Health’s performance?

Revenue growth alone is a weak scorecard for a health insurer. The strongest research process follows membership, pricing, claims, risk adjustment, administrative leverage, and capital together.

What should a dashboard emphasize next?

What opportunities and risks could change Oscar Health’s outlook?

Oscar’s largest opportunity is the continued migration of consumers into individually selected coverage. ICHRA arrangements can convert employer benefit dollars into individual-market purchasing power, potentially expanding Oscar’s addressable market while using its existing insurance and shopping infrastructure. The Lucie marketplace, brokerage assets, and healthinsurance.org audience may reduce friction in plan comparison and enrollment. Greater membership can also spread technology and corporate costs across a larger premium base.

Which risks are most material?

Oscar’s annual report risk factors emphasize medical-cost estimation, risk adjustment, regulation, premium subsidies, provider relationships, statutory capital, reinsurance, cybersecurity, competition, AI and machine-learning uncertainty, and the controlled-company structure. The 2025 loss demonstrates that these are operating risks, not theoretical disclosures. A few percentage points of MLR deterioration can erase hundreds of millions of dollars of earnings.

Why does Oscar Health matter for valuation?

Oscar is difficult to value with a simple revenue multiple because premium revenue carries medical obligations and regulatory capital requirements. A DCF should begin with membership growth and premium yield, then model medical loss ratio, SG&A leverage, investment income, taxes, capitalized software, statutory capital needs, and share dilution from convertible securities and equity compensation.

What assumptions drive intrinsic value most?

Comparable-company analysis should separate Oscar from diversified managed-care groups with large Medicare, Medicaid, pharmacy-benefit, and employer businesses. Oscar deserves comparison on individual-market growth, MLR, administrative ratio, capital adequacy, and technology monetization. The strongest valuation evidence would be several consecutive full years of underwriting profitability rather than one seasonally favorable quarter.

What is the key takeaway from Oscar Health analysis?

Oscar matters because it has become a scaled test of whether a technology-led, consumer-oriented insurer can compete in the highly regulated ACA market. Its 3.17 million members and $4.65 billion of Q1 2026 revenue show that the company is no longer a small startup. Its digital platform, broker reach, selected provider networks, ICHRA strategy, and consumer shopping assets create real differentiation.

The evidence also argues for caution in interpretation. FY2025 revenue growth coincided with a $443.2 million net loss as medical costs and risk adjustment overwhelmed administrative leverage. Q1 2026 then produced $679.0 million of net income, illustrating both the potential earnings power and the seasonality of the model. Ownership is another defining feature: Thrive-affiliated entities held 68.0% of combined voting power as of April 10, 2026, giving founder-linked capital decisive control despite a much smaller economic stake.